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Abstract
AIM: The objective of the study was to determine the inhibitory effect of bay leaf (Syzygium polyanthum) on matrix 
metalloproteinases (MMPs) (MMP-9 and MMP-13) inhibitory effect in surgery-induced acute coronary syndrome 
(ACS) rat model.
METHODS: This study was experimental animal study. Thirty-two surgery-induced ACS Wistar rats (Rattus 
norvegicus) divided into 16 bay leaf extract (treatment) group and 16 control groups were sacrificed on days 1, 3, 
7, and 14 after induction. Expressions of MMP-9 and MMP-13 were determined by immunohistochemistry and its 
scoring was assessed by two-blinded experienced pathologists. The immunohistochemical scoring of MMP-9 and 
MMP-13 between groups was analyzed using independent sample t-test and within groups by using one-way ANOVA 
test.
RESULTS: The expression of MMP-13 in treatment group was decreased compared to control group on days 7 and 
14 (p = 0.001 and p = 0.015, respectively). Compared to day 1, the reduction expression of MMP-13 was significant 
in both control group and treatment group (p = 0.009 and p = 0.003, respectively). There were no significant changes 
in expression of MMP-9 between groups, and within control group and treatment group.
CONCLUSION: Bay leaf can reduce the overexpression of MMP-13 in surgery-induced ACS rat model. Bay leaf 
extract can be considered to be given as an adjuvant to prevent cardiovascular adverse event and adverse cardiac 
remodeling post-ACS.
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Introduction
Coronary heart disease is one of the major 
causes of mortality in people older than 35 years 
that were usually caused by atherosclerotic process 
in coronary arteries, better known as coronary 
artery disease (CAD) [1]. Acute coronary syndrome 
(ACS) is symptomatic CAD and further classified 
into ST-elevation acute myocardial infarction and 
non-ST-elevation ACSs [2]. Progression of ACS is 
thought as a result from sudden luminal narrowing 
by thrombosis, mostly by plaque rupture [3]. Plaque 
rupture is caused by destruction of extracellular 
matrix due to increased production of matrix 
metalloproteinases (MMPs) by macrophages during 
atherosclerosis process in response to inflammatory 
stimuli and oxidative stress [4], [5].
Some MMPs (such as MMP-9 and 
MMP-13) have important role in cardiovascular 
diseases and myocardial remodeling, especially in 
ACS [6], [7]. Gelatinase B, widely known for MMP-9, 
degrades Type IV collagen and elastin [8] and increased 
concentration was associated with plaque rupture during 
acute phase of ACS [9]. As MMP-9 can differentiate 
ACS with ruptured plaques from non-ruptured plaques, 
it might have a predictive value of mortality [10] and 
correlate to acute heart failure event [11]. Whereas, 
MMP-13 has role in platelet aggregation and thrombus 
formation and correlates positively with enhanced 
plaque vulnerability and rupture [7].
Bay leaf (Syzygium polyanthum), better 
known as salam leaf in Indonesia, is an easily 
accessible traditional Indonesian herbal medicine 
with many pharmacological activities, such as 
anti-inflammatory, antioxidant, anticholesterol, 
and antiplatelet [12], [13]. Flavonoid, tannin, and 
saponin compounds were suspected to be the 
active compound in bay leaf to reduce cholesterol 
level, arterial damage protection, and deposition 
of cholesterol on arterial endothelium [12], [14] by 
modulating MMPs [15], [16]. Flavonoid has inhibitory 
effect on overexpressed MMPs in cardiovascular 
disease [17]. This study aims to demonstrate the 
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MMPs (MMP-9 and MMP-13) inhibitory effect of bay 
leaf on rat model with ACS.
Methods
Animals and study design
This study was experimental animal study. 
Animal handling was conducted in Animal House, 
Research Laboratory, School of Medicine, Universitas 
Brawijaya, Malang, Indonesia. Histopathological 
analysis was conducted in Biochemical and Molecular 
Biology Laboratory of the Medical Faculty of Universitas 
Brawijaya Malang, Indonesia. All procedures were 
conducted in December 2019. The experiment was 
approved by The Institutional Ethics Committee of 
Universitas Sumatera Utara, Medan, Indonesia.
Thirty-two male healthy Wistar rats (Rattus 
norvegicus), 10–12 weeks old and weighing 200 g, 
were housed at 20–25°C with controlled 12 h light/dark 
cycle. Laboratory-standardized cages were used to 
keep the animals with free access to food and water. 
Thirty-two surgical-induced myocardial infarction 
rats were divided into two groups: Control group 
(16 rats) and treatment group (16 rats). Treatment 
group was given ethanol extract of bay leaf in sodium 
carboxymethyl cellulose (3.6 mg/rats) [18] through 
orogastric tube. Bay leaf (S. polyanthum) extract 
was prepared by maceration [19] in the research 
unit laboratory, School of Medicine, Universitas 
Brawijaya, Malang, Indonesia. Four rats each from 
both groups were sacrificed on days 1, 3, 7, and 14. 
Immunohistochemical analysis of MMP9 and MMP13 
was conducted to these rats.
Surgical induction of myocardial infarction
The experimental myocardial induction 
was done by ligation of coronary artery [13]. Rat 
was anesthetized by ketamine before the surgery. 
Thoracotomy followed by permanent ligation of left 
anterior descending artery was conducted until sign of 
myocardial induction was seen (blanching area distal to 
the ligation) [20]. Thorax and skin were sutured and rat 
was left to recover.
Immunohistochemical analysis of MMP9 
and MMP13
The heart specimens were paraffin-embedded 
and subsequently cut into 4 to 6 micron thick using 
microtome. The chosen paraffin-embedded slides were 
deparaffinized, rehydrated, and heated on microwave 
with 10 mM sodium citrate buffer (pH 6.0) for 10 min 
at 95°C, then allow the slides to cool in the buffer for 
20 min. Endogen peroxidase activity was blocked with 
1% hydrogen peroxide for 5 min, and then washed with 
PBS twice for 5 min each. The specimens were incubated 
overnight in 4 °C, and then immune stained with MMP-9 
antibody (E-11; sc-393859) and MMP-13 antibody 
(H-230; sc-30073) primary antibodies from Santa Cruz 
Biotechnology, Inc. (Dallas, TX, USA) in concentration 
of 200 µg/mL diluted by 1:1000. Primary antibody 
was detected by avidin-biotin peroxidase solution 
(VECTASTAIN Elite ABC kit) from Vector Laboratories 
(Burlingame, CA, USA) and signal was visualized 
by using 3,3’-diaminobenzidine from Sigma-Aldrich 
(Missouri, USA). The slides then counterstained with 
hematoxylin and assessed by two-blinded experienced 
pathologists. Slides were scored for positive cells and 
intensity of staining. Positive cells were scored as (0) for 
<10% stained, (1) for 10–25% stained, (2) for 25–50% 
stained, (3) for 50–75% stained, and (4) for 75–100% 
stained. Intensity of staining was scored as (1) for weak 
intensity, (2) for moderate, and (3) for strong intensity. 
Slides scoring of immunohistochemical staining was 
positive cells multiplied by intensity of staining.
Statistical analysis
The immunohistochemical scoring of MMP-9 
and MMP-13 between groups was analyzed using 
independent sample t-test (normal data distribution) 
or Mann–Whitney U-test (data distribution not normal). 
The results were also analyzed using one-way ANOVA 
test (normal data distribution) or Kruskal–Wallis test 
(data distribution not normal) to compare between 
days within treatment group and also control group. 
Bonferroni post hoc test were conducted if there was 
significant differences using one-way ANOVA test. 
Mann–Whitney U-test comparing day 1 with each day 
3, 7, and 14 was conducted if there were significant 
differences using Kruskal–Wallis test. The differences 
were considered statistically significant when p < 0.05.
Results
Slides were examined for the expression of MMP-9 
(Figure 1) and MMP-13 (Figure 2), then were compared 
between groups by immunohistochemistry scoring on 
days 1, 3, 7, and 14 (Table 1). The immunohistochemistry 
score of MMP-13 was significantly lower in treatment 
group compared to control group on days 7 and 14 
(p = 0.001 and p = 0.015, respectively). Compared to day 
1, there was significant decrease in immunohistochemistry 
score of MMP-13 on either control group (F(3,12) = 
6.044, p = 0.009) and treatment group (F(3,12) = 7.952, 
p = 0.003). From post hoc analysis, immunohistochemistry 
score of MMP-13 from control group was significantly 
decreased on days 3, 7, and 14 (p = 0.044, p = 0.028, 
and p = 0.019, respectively) compared to day 1, and from 
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Figure 1: Immunohistological slides of matrix metalloproteinases 
(MMP)-9 expression on myocardial of surgical-induced acute 
coronary syndrome (ACS) rats. Row 1 shows myocardial MMP-9 
expression of surgically-induced ACS rats without treatment, whereas 
Row 2 shows myocardial MMP-9 expression of surgically-induced 
ACS rats with bay leaf extract as treatment. Black arrow indicates the 
expression of MMP-9
treatment group was significantly decreased only on days 
7 and 14 (p = 0.024 and p = 0.004) (Figure 3). There 
were no significant changes in expression of MMP-9 on 
treatment group compared to control group, and when 
compared to day 1, there were no significant changes in 
immunohistochemistry score of MMP-9 on either control 
or treatment groups (Figure 4).
Figure 2: Immunohistological slides of matrix metalloproteinases 
(MMP)-13 expression on myocardial of surgical-induced acute 
coronary syndrome (ACS) rats. Row 1 shows myocardial MMP-13 
expression of surgically-induced ACS rats without treatment, whereas 
Row 2 shows myocardial MMP-13 expression of surgically-induced 
ACS rats with bay leaf extract as treatment. Black arrow indicates the 
expression of MMP-13
Discussion
Atherosclerotic plaque rupture can be caused 
by overexpression of MMPs, especially MMP-9 and 
MMP-13 [4], [7], [10]. Higher serum MMP-9 was 
found in acute phase of ACS and gradually resolves 
during recovery [9]. Bay leaf extract has flavonoid 
compound that reduces cholesterol level, protecting 
arteries from damage, and reducing deposition of 
cholesterol on arterial endothelium [12], [14] by 
inhibiting overexpressed MMPs in cardiovascular 
disease [15], [16], [17]. This finding, however, is 
discordant to our study which shows there were no 
significant differences of MMP-9 expression between 
control and group treatment, within control group, 
and within treatment group. This discordant result 
might be due to MMP-9 was undetectable in the 
infarcted region, but higher in remote region [21] and 
due to differences between expression of MMP-9 in 
rats and humans [4]. Study by Huang et al., shows 
higher expression of MMP-9 in human compared to 
rats [22].
Table 1: Comparison of MMP-9 and MMP-13 on immunohistochemistry score between control group and treatment group*
Day Immunohistochemistry score (mean [SD])*
MMP-9 MMP-13
Control 
group
Treatment 
group
Mean difference 
(95% CI)
t-statistic 
(df)
p Control 
group
Treatment 
group
Mean difference 
(95% CI)
t-statistic 
(df)
p
1 9.00 (1.63) 8.25 (1.89) 0.75 (‒ 2.3, 3.8) 0.60 (6) 0.570 15.75 (1.71) 13.75 (2.22) 2.00 (‒ 1.42, 5.42) 1.43 (6) 0.203
3 7.75 (2.50) 9.25 (1.26) ‒ 1.50 (‒ 4.92, 1.92) ‒ 1.07 (6) 0.325 12.25 (1.71) 10.25 (2.75) 2.00 (‒ 1.96, 5.96) 1.23 (6) 0.263
7 9.50 (3.42) 7.50 (2.52) 2.00 (‒ 3.20, 7.20) 0.94 (6) 0.382 12.00 (0.82) 7.75 (1.26) 4.25 (2.41, 6.09) 5.67 (6) 0.001
14 8.75 (2.50) 7.25 (1.71) 1.50 (‒ 2.20, 5.20) 0.99 (6) 0.360 11.75 (1.71) 6.00 (2.94) 5.75 (1.59, 9.91) 3.38 (6) 0.015
*Score: Positive cells*signal intensity; positive cells: (1) for 0 ‒ 24%, (2) for 25 ‒ 50%, (3) for 51 ‒ 75%, and (4) for 76 ‒ 100% stained cells for MMP-9 and MMP-13; signal intensity: (1) for weak intensity, (2) for moderate 
intensity, and (3) for strong intensity.
Figure 3: Expression of matrix metalloproteinases-13 on acute 
coronary syndrome rat model compared between treatment and 
control groups
Figure 4: Expression of matrix metalloproteinases-9 on acute 
coronary syndrome rat model compared between treatment and 
control groups
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In vitro study by Howes et al. shows MMP-
13 role in platelet aggregation inhibition and thrombus 
formation [23]. This protease is upregulated in 
atherothrombotic and inflammatory conditions [24]. 
Higher level of MMP-13 enhanced plaque vulnerability 
and rupture of plaques [25]. Study by Wilson et al., 
shows there is increased MMP-13 expression in 
infarcted region [21]. Our study shows there are 
significant reduction in MMP-13 expression in bay leaf 
extract ACS-induced rat compared to control. This 
finding might be resulted from flavonoid compound 
of bay leaf extract which inhibits expression of 
MMPs [15], [16], [17]. Although there were significant 
decrease in MMP-13 expression in both control and 
treatment compared to day 1, there was always lower 
MMP-13 expression on treatment group compared to 
control. Inhibition of MMP-13 overexpression yields to 
collagen accumulation in plaques therefore increases 
the rupture resistance of plaques [26].
Reducing the overexpression of MMPs in 
heart disease may modify adverse the development of 
cardiac remodeling [6]. Although there were differences 
between human and rat expression of MMPs [4] which 
are within our limitation of study, this study shows the 
promising bay leaf pharmacological potential inhibition 
of MMP-13 in reducing cardiovascular adverse event 
and development of better cardiac remodeling post-
ACS. Flavonoid active compound of bay leaf extract 
which might be responsible in modification of MMPs 
expression should be identified further for the potential 
in myocardial infarction.
Conclusion
Bay leaf can reduce the overexpression of 
MMP-13 in surgery-induced ACS rat model. Bay leaf 
extract can be considered to be given as an adjuvant 
to prevent cardiovascular adverse event and adverse 
cardiac remodeling post-ACS.
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